<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364732">
  <stage>Registered</stage>
  <submitdate>5/08/2013</submitdate>
  <approvaldate>12/08/2013</approvaldate>
  <actrnumber>ACTRN12613000897763</actrnumber>
  <trial_identification>
    <studytitle>Effect of zinc on standard pharmacotherapy hepatitis C treatment</studytitle>
    <scientifictitle>Effect of zinc addition on viral response in hepatitis C and beta thalassemia major patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>hepatitis C patients</healthcondition>
    <healthcondition>beta thalassemia major</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Addition of oral zinc(30 mg /d elemental) for 48 weeks  to standard pharmacotherapy of hepatitis C (peg interferon alfa plus ribavirin) Duration of standard therapy will be 48 weeks too. In other words, peg interferon,ribavirin,zinc/placebo will be start with each other for 48 weeks.
adherence monitoring with  tablet return
</interventions>
    <comparator>placebo ( microcellulose tablet)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sustained viral response (SVR) with PCR (Polymerase Chain Reaction) method
Definition of SVR:absence of detectable RNA of the hepatitis C virus in plasma for at least 6 months after discontinuing the treatment</outcome>
      <timepoint>after 48 weeks all medicine will be discontinue (standard pharmacotherapy with peg interferon plus ribavirin) and zinc/placebo. determination of SVR 6 months after withdrawal of medicines. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>none</outcome>
      <timepoint>none</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>60 patients with recent diagnosis of chronic hepatitis C and previous diagnosis of beta thalassemia major </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>hepatitis B and human immunodeficiency viruses infected, recieving zinc or any complement containing zinc</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>10/07/2012</anticipatedstartdate>
    <actualstartdate>10/07/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate>10/12/2013</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Shahid Beheshti University of Medical Sciences</primarysponsorname>
    <primarysponsoraddress>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran Shahid Beheshti University of Medical Sciences PO box: 14397-65461 </primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Shahid Beheshti University of Medical Sciences</fundingname>
      <fundingaddress>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran  PO box: 14397-65461</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress>none</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In previous studies the addition of zinc to standard therapy of hepatitis C induced limited benefits on viral response and some of these studies have reported improved transaminases with zinc therapy. It is important to notice that a group of the hepatitis C patients have beta thalassemia major as well and combination therapy with INF-a plus ribavirin should be suggested for them . Zinc depletion has been reported in patients with beta thalassemia major under treatment of chelator agents such as deferioxamine, deferiprone and deferasirox. Using of zinc accompanied with standard regimen may have a benefit in pharmacotherapy of chronic hepatitis C with beta thalassemia major.So the aim of present study was to evaluate the effect of zinc administration on viral response in patients with chronic hepatitis </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Mohammad Abbasinazari</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran Shahid Beheshti University of Medical Sciences PO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mohammad Abbasinazari</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran  Shahid Beheshti University of Medical SciencesPO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mohammad Abbasinazari</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran Shahid Beheshti University of Medical Sciences PO box: 14397-65461</address>
      <phone>+ 98 2188873704</phone>
      <fax />
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mohammad Abbasinazari</name>
      <address>Velenjak, near Talighani hospital, 3rd street, Tehran,Tehran, Iran  PO box: 14397-65461</address>
      <phone>+98 2188873704</phone>
      <fax />
      <email>farshadpharm@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>